NASDAQ:TXMD - TherapeuticsMD Stock Price, Price Target & More

Get Started

$6.40 +0.31 (+5.09 %)

(As of 05/27/2018 04:00 PM ET)

Previous Close$6.40

Today's Range$6.10 - $6.52

52-Week Range$3.83 - $7.01

Volume4.53 million shs

Average Volume2.90 million shs

Market Capitalization$1.39 billion

P/E Ratio-17.30

Dividend YieldN/A

Beta1.34

About TherapeuticsMD (NASDAQ:TXMD)

TherapeuticsMD, Inc. operates as a women's health care product company. Its pipeline of hormone therapy drug candidates include TX-001HR, a combination of estradiol and progesterone drug candidate under clinical trials for the treatment of moderate to severe vasomotor symptoms due to menopause; TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil; and TX-004HR, an applicator-free vaginal estradiol softgel drug candidate for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy in post-menopausal women with vaginal linings that do not receive enough estrogen. The company also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaMedMD and BocaGreenMD brands. It markets its products primarily through a direct national sales force to health care providers in the OB/GYN market space. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.

Receive TXMD News and Ratings via Email

Sign-up to receive the latest news and ratings for TXMD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

SymbolNASDAQ:TXMD

CUSIPN/A

Webwww.therapeuticsmd.com

Phone561-961-1900

Debt

Debt-to-Equity RatioN/A

Current Ratio7.61

Quick Ratio7.51

Price-To-Earnings

Trailing P/E Ratio-17.30

Forward P/E Ratio-15.61

P/E GrowthN/A

Sales & Book Value

Annual Sales$16.78 million

Price / Sales82.61

Cash FlowN/A

Price / CashN/A

Book Value$0.50 per share

Price / Book12.80

Profitability

EPS (Most Recent Fiscal Year)($0.37)

Net Income$-76,920,000.00

Net Margins-483.98%

Return on Equity-66.77%

Return on Assets-60.12%

Miscellaneous

Employees173

Outstanding Shares216,580,000

TherapeuticsMD (NASDAQ:TXMD) Frequently Asked Questions

What is TherapeuticsMD's stock symbol?

TherapeuticsMD trades on the NASDAQ under the ticker symbol "TXMD."

How were TherapeuticsMD's earnings last quarter?

TherapeuticsMD Inc (NASDAQ:TXMD) posted its quarterly earnings results on Thursday, May, 3rd. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.10) by $0.01. The company had revenue of $3.77 million for the quarter, compared to analyst estimates of $4.18 million. TherapeuticsMD had a negative return on equity of 66.77% and a negative net margin of 483.98%. The business's revenue for the quarter was down 5.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.11) earnings per share. View TherapeuticsMD's Earnings History.

What price target have analysts set for TXMD?

9 brokerages have issued 12-month target prices for TherapeuticsMD's stock. Their forecasts range from $6.00 to $28.00. On average, they anticipate TherapeuticsMD's share price to reach $14.8571 in the next year. View Analyst Ratings for TherapeuticsMD.

Are investors shorting TherapeuticsMD?

TherapeuticsMD saw a decrease in short interest in the month of May. As of May 15th, there was short interest totalling 55,097,382 shares, a decrease of 4.2% from the April 30th total of 57,526,791 shares. Based on an average daily volume of 2,752,132 shares, the days-to-cover ratio is currently 20.0 days. Approximately 31.8% of the company's stock are short sold.

Who are some of TherapeuticsMD's key competitors?

Some companies that are related to TherapeuticsMD include GALAPAGOS NV/S (GLPG), Catalent (CTLT), Agios Pharmaceuticals (AGIO), Loxo Oncology (LOXO), Dr. Reddy's Laboratories (RDY), Taro Pharmaceutical Industries (TARO), United Therapeutics (UTHR), GW Pharmaceuticals (GWPH), FibroGen (FGEN), Ligand Pharmaceuticals (LGND), Hutchison China MediTech (HCM), Blueprint Medicines (BPMC), Ultragenyx Pharmaceutical (RARE), Array Biopharma (ARRY) and Amicus Therapeutics (FOLD).

Who are TherapeuticsMD's key executives?

TherapeuticsMD's management team includes the folowing people:

Mr. Robert G. Finizio, Co-Founder, CEO & Director (Age 47)
Mr. John C. K. Milligan IV, Pres, Sec. & Director (Age 56)
Dr. Brian A. Bernick, Co-Founder, Chief Clinical Officer & Director (Age 50)
Mr. Daniel Alan Cartwright, CFO, Treasurer & Principal Accounting Officer (Age 60)
Mr. Mitchell L. Krassan, Chief Strategy Officer and Exec. VP (Age 52)

Has TherapeuticsMD been receiving favorable news coverage?

News headlines about TXMD stock have trended somewhat positive on Sunday, Accern reports. The research firm identifies positive and negative press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. TherapeuticsMD earned a media sentiment score of 0.17 on Accern's scale. They also gave headlines about the company an impact score of 46.95 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.

Who are TherapeuticsMD's major shareholders?

TherapeuticsMD's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include JPMorgan Chase & Co. (9.08%), BlackRock Inc. (6.43%), Franklin Resources Inc. (4.88%), Stifel Financial Corp (0.86%), First Eagle Investment Management LLC (0.81%) and OppenheimerFunds Inc. (0.76%). View Institutional Ownership Trends for TherapeuticsMD.

Which institutional investors are selling TherapeuticsMD stock?

TXMD stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Franklin Resources Inc., Guggenheim Capital LLC, Teacher Retirement System of Texas, Claraphi Advisory Network LLC and California State Teachers Retirement System. View Insider Buying and Selling for TherapeuticsMD.

Which institutional investors are buying TherapeuticsMD stock?

TXMD stock was purchased by a variety of institutional investors in the last quarter, including First Eagle Investment Management LLC, DekaBank Deutsche Girozentrale, GSA Capital Partners LLP, Trellus Management Company LLC, Iridian Asset Management LLC CT, Cubist Systematic Strategies LLC, Schwab Charles Investment Management Inc. and Barclays PLC. View Insider Buying and Selling for TherapeuticsMD.

How do I buy shares of TherapeuticsMD?

Shares of TXMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is TherapeuticsMD's stock price today?

One share of TXMD stock can currently be purchased for approximately $6.40.

How big of a company is TherapeuticsMD?

TherapeuticsMD has a market capitalization of $1.39 billion and generates $16.78 million in revenue each year. The company earns $-76,920,000.00 in net income (profit) each year or ($0.37) on an earnings per share basis. TherapeuticsMD employs 173 workers across the globe.

How can I contact TherapeuticsMD?

TherapeuticsMD's mailing address is 6800 BROKEN SOUND PARKWAY NW, BOCA RATON FL, 33487. The company can be reached via phone at 561-961-1900 or via email at [email protected]

MarketBeat Community Rating for TherapeuticsMD (TXMD)

Community Ranking:		2.9 out of 5 ( )
Outperform Votes:		162 (Vote Outperform)
Underperform Votes:		115 (Vote Underperform)
Total Votes:		277

MarketBeat's community ratings are surveys of what our community members think about TherapeuticsMD and other stocks. Vote "Outperform" if you believe TXMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TXMD will underperform the S&P 500 over the long term. You may vote once every thirty days.

TherapeuticsMD (NASDAQ:TXMD) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

9 Wall Street analysts have issued ratings and price targets for TherapeuticsMD in the last 12 months. Their average twelve-month price target is $14.8571, suggesting that the stock has a possible upside of 132.14%. The high price target for TXMD is $28.00 and the low price target for TXMD is $6.00. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	2.89	2.89	2.89	2.91
Ratings Breakdown:	0 Sell Rating(s) 1 Hold Rating(s) 8 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 1 Hold Rating(s) 8 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 1 Hold Rating(s) 8 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 1 Hold Rating(s) 10 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$14.8571	$14.50	$14.50	$14.7222
Price Target Upside:	132.14% upside	184.31% upside	189.42% upside	130.01% upside

TherapeuticsMD (NASDAQ:TXMD) Consensus Price Target History

Price Target History for TherapeuticsMD (NASDAQ:TXMD)

TherapeuticsMD (NASDAQ:TXMD) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
5/3/2018	Oppenheimer	Set Price Target	Buy	$10.00	High
3/9/2018	Noble Financial	Reiterated Rating	Buy		Medium
1/7/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$28.00	Low
12/20/2017	Deutsche Bank	Set Price Target	Buy	$9.00	High
11/6/2017	Cowen	Reiterated Rating	Outperform	$13.00 ➝ $16.00	N/A
9/26/2017	Jefferies Group	Reiterated Rating	Buy	$15.00	Medium
9/8/2017	Morgan Stanley	Initiated Coverage	Equal Weight	$6.00	N/A
8/21/2017	Stifel Nicolaus	Reiterated Rating	Buy	$20.00	Low
7/11/2017	CIBC	Upgrade	Market Perform ➝ Outperform		High
12/6/2016	Guggenheim	Reiterated Rating	Positive		N/A
12/4/2016	Goldman Sachs Group	Reiterated Rating	Buy	$10.50	N/A

(Data available from 5/27/2016 forward)

TherapeuticsMD (NASDAQ:TXMD) Earnings History and Estimates Chart

Earnings by Quarter for TherapeuticsMD (NASDAQ:TXMD)

TherapeuticsMD (NASDAQ:TXMD) Earnings Estimates

2018 EPS Consensus Estimate: ($0.43)

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	2	($0.10)	($0.08)	($0.09)
Q2 2018	2	($0.11)	($0.10)	($0.11)
Q3 2018	2	($0.12)	($0.10)	($0.11)
Q4 2018	2	($0.15)	($0.09)	($0.12)

TherapeuticsMD (NASDAQ TXMD) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
5/3/2018	Q1 2018	($0.10)	($0.11)	$4.18 million	$3.77 million	View	N/A
2/20/2018	Q4 2017	($0.09)	($0.10)	$4.66 million	$4.13 million	View	Listen
11/6/2017	Q3 2017	($0.10)	($0.0710)	$5.36 million	$4.42 million	View	N/A
8/3/2017	Q2 2017	($0.11)	($0.10)	$4.91 million	$4.25 million	View	Listen
5/2/2017	Q1 2017	($0.11)	($0.11)	$5.29 million	$3.99 million	View	N/A
2/23/2017	Q416	($0.12)	($0.12)	$5.91 million	$4.49 million	View	Listen
11/3/2016	Q316	($0.11)	($0.13)	$5.76 million	$5.50 million	View	N/A
8/4/2016	Q216	($0.10)	($0.11)	$5.63 million	$4.40 million	View	N/A
5/3/2016	Q116	($0.09)	($0.11)	$5.73 million	$4.93 million	View	N/A
2/25/2016	Q415	($0.10)	($0.10)	$5.33 million	$5.63 million	View	Listen
11/4/2015	Q315	($0.12)	($0.11)	$5.01 million	$5.19 million	View	N/A
8/6/2015	Q215	($0.11)	($0.16)	$4.65 million	$4.80 million	View	Listen
5/5/2015		($0.10)	($0.13)	$4.34 million	$4.48 million	View	N/A
3/10/2015	Q414	($0.09)	($0.10)	$2.86 million	$4.26 million	View	N/A
11/6/2014	Q3 14	($0.08)	($0.12)	$3.90 million	$4.19 million	View	N/A
8/6/2014	Q2 2014	($0.08)	($0.07)	$3.12 million	$3.75 million	View	N/A
5/6/2014	Q1 14	($0.06)	($0.06)	$3.08 million	$2.80 million	View	N/A
3/3/2014	Q213	($0.06)	($0.06)	$2.72 million	$2.90 million	View	N/A
11/4/2013	Q3 2013	($0.04)	($0.06)	$2.55 million	$2.30 million	View	N/A
8/6/2013	Q2 2013	($0.06)	($0.05)	$1.51 million	$2.08 million	View	N/A
5/8/2013	Q113	($0.06)	($0.06)	$1.32 million	$1.50 million	View	N/A
3/12/2013	Q4 2012	($0.06)	($0.05)			View	N/A
11/13/2012	Q3 2012	($0.04)	($0.04)			View	N/A

(Earnings results data provided by Zacks Investment Research)

TherapeuticsMD (NASDAQ:TXMD) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

TherapeuticsMD (NASDAQ TXMD) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 22.85%
Institutional Ownership Percentage: 72.70%

Insider Trading History for TherapeuticsMD (NASDAQ:TXMD)

Institutional Ownership by Quarter for TherapeuticsMD (NASDAQ:TXMD)

TherapeuticsMD (NASDAQ TXMD) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/8/2017	Tommy G Thompson	Director	Buy	5,000	$6.21	$31,050.00	3,555
8/30/2017	Tommy G Thompson	Director	Buy	5,000	$5.99	$29,950.00	3,555
3/11/2016	Cooper C Collins	Director	Buy	16,000	$6.23	$99,680.00	36,000
8/25/2015	Angus C Russell	Director	Buy	13,500	$5.98	$80,730.00	48,500
6/8/2015	Mitchell Krassan	EVP	Sell	30,000	$8.18	$245,400.00
5/12/2015	Angus C Russell	Director	Buy	35,000	$6.15	$215,250.00
5/11/2015	Tommy G Thompson	Chairman	Buy	6,000	$6.09	$36,540.00
5/8/2015	J Martin Carroll	Director	Buy	10,000	$6.11	$61,100.00
11/21/2014	Daniel A Cartwright	CFO	Sell	40,000	$3.91	$156,400.00
9/4/2014	Tommy G Thompson	Director	Buy	1,757	$5.44	$9,558.08
6/5/2014	Cooper C Collins	Director	Buy	20,000	$3.84	$76,800.00
5/9/2014	Robert Lapenta, Jr.	Director	Buy	5,000	$3.66	$18,300.00	10,000
5/8/2014	Tommy Thompson	Director	Buy	14,000	$3.57	$49,980.00
3/26/2014	Brian Bernick	Director	Sell	421,268	$6.70	$2,822,495.60	297,000
3/26/2014	John C.K. Iv Milligan	Insider	Sell	353,412	$6.70	$2,367,860.40	1,722,419
3/26/2014	Robert Finizio	CEO	Sell	982,053	$6.70	$6,579,755.10	21,029,533
3/10/2014	Mitchell Krassan	EVP	Sell	7,500	$7.73	$57,975.00
2/26/2014	John C.K. Iv Milligan	President	Sell	25,000	$6.31	$157,750.00	6,318,018
2/21/2014	Robert Finizio	CEO	Sell	50,000	$6.17	$308,500.00	22,011,586
2/12/2014	Brian Bernick	Director	Sell	31,250	$6.16	$192,500.00
1/30/2014	John C.K. Iv Milligan	Insider	Sell	25,000	$6.16	$154,000.00	6,343,018
1/23/2014	Robert G Finizio	CEO	Sell	50,000	$5.70	$285,000.00
1/13/2014	Mitchell Krassan	EVP	Sell	7,500	$5.73	$42,975.00
1/8/2014	Brian Bernick	Director	Sell	31,250	$5.13	$160,312.50
8/26/2013	Brian Bernick	Insider	Sell	1,600,000	$1.55	$2,480,000.00
8/26/2013	Jules A Musing	Director	Buy	5,282	$2.15	$11,356.30
6/14/2013	Cooper C Collins	Director	Sell	2,631,579	$1.75	$4,605,263.25

(Data available from 1/1/2013 forward)

TherapeuticsMD (NASDAQ TXMD) News Headlines

Source:

Date	Headline
	Short Interest in TherapeuticsMD Inc (TXMD) Decreases By 4.2% www.americanbankingnews.com - May 27 at 3:16 AM
	The Week Ahead In Biotech: ASCO Presentations In The Spotlight feeds.benzinga.com - May 26 at 1:12 PM
	Cantor Fitzgerald Research Analysts Decrease Earnings Estimates for TherapeuticsMD Inc (TXMD) www.americanbankingnews.com - May 24 at 8:32 AM
	TherapeuticsMD shares halted pending news seekingalpha.com - May 24 at 8:21 AM
	TherapeuticsMD (TXMD) Has Not Been Informed by FDA About Status of TX-004HR NDA www.streetinsider.com - May 23 at 5:34 PM
	TherapeuticsMD Says Imvexxy Awaits May PDUFA Date, Doesn't Acknowledge Website Error www.benzinga.com - May 23 at 5:34 PM
	TherapeuticsMD Comments on Media Reports Regarding TX-004HR finance.yahoo.com - May 23 at 5:34 PM
	$4.13 Million in Sales Expected for TherapeuticsMD Inc (TXMD) This Quarter www.americanbankingnews.com - May 21 at 4:22 AM
	Brokerages Anticipate TherapeuticsMD Inc (TXMD) to Announce -$0.12 Earnings Per Share www.americanbankingnews.com - May 19 at 9:25 AM
	TherapeuticsMD Announces Investor and Analyst Day on June 4 finance.yahoo.com - May 16 at 5:40 PM
	TikaMobile Selected by TherapeuticsMD as Business Intelligence Platform Provider globenewswire.com - May 16 at 8:20 AM
	TherapeuticsMD Sees Unusually Large Options Volume (TXMD) www.americanbankingnews.com - May 16 at 6:46 AM
	TherapeuticsMD (TXMD) Upgraded at Zacks Investment Research www.americanbankingnews.com - May 9 at 6:51 PM
	TherapeuticsMD (TXMD) Lifted to "Buy" at ValuEngine www.americanbankingnews.com - May 8 at 3:29 PM
	FY2020 EPS Estimates for TherapeuticsMD Inc Lowered by Oppenheimer (TXMD) www.americanbankingnews.com - May 7 at 5:17 AM
	TherapeuticsMD's (TXMD) CEO Robert Finizio on Q1 2018 Results - Earnings Call Transcript seekingalpha.com - May 5 at 8:28 AM
	Oppenheimer Reiterates $10.00 Price Target for TherapeuticsMD (TXMD) www.americanbankingnews.com - May 4 at 10:31 PM
	Edited Transcript of TXMD earnings conference call or presentation 3-May-18 8:30pm GMT finance.yahoo.com - May 4 at 5:32 PM
	TherapeuticsMD (TXMD) Posts Quarterly Earnings Results, Misses Estimates By $0.01 EPS www.americanbankingnews.com - May 4 at 3:32 PM
	TherapeuticsMD: 1Q Earnings Snapshot finance.yahoo.com - May 4 at 8:19 AM
	BRIEF-Therapeutics MD Reports Loss Per Share Of $0.11 www.reuters.com - May 3 at 5:23 PM
	TherapeuticsMD Announces First Quarter 2018 Financial Results finance.yahoo.com - May 3 at 5:23 PM
	$4.10 Million in Sales Expected for TherapeuticsMD Inc (TXMD) This Quarter www.americanbankingnews.com - May 3 at 2:30 AM
	TherapeuticsMD (TXMD) Rating Increased to Hold at ValuEngine www.americanbankingnews.com - May 2 at 3:48 PM
	Zacks: Brokerages Anticipate TherapeuticsMD Inc (TXMD) to Post -$0.10 EPS www.americanbankingnews.com - May 1 at 7:14 PM
	TherapeuticsMD to Host First Quarter Financial Results Conference Call and Webcast on May 3 finance.yahoo.com - May 1 at 5:17 PM
	Drug Makers Stocks' Research Reports Released on Sanofi, Shire, TherapeuticsMD, and Zogenix www.prnewswire.com - April 26 at 8:18 AM
	TherapeuticsMD (TXMD) Downgraded by Zacks Investment Research www.americanbankingnews.com - April 25 at 2:58 PM
	TherapeuticsMD (TXMD) Rating Lowered to Sell at Zacks Investment Research www.americanbankingnews.com - April 18 at 2:28 PM
	Analysts Anticipate TherapeuticsMD Inc (TXMD) Will Post Quarterly Sales of $4.10 Million www.americanbankingnews.com - April 16 at 2:19 AM
	TherapeuticsMD Inc (TXMD) Expected to Post Earnings of -$0.10 Per Share www.americanbankingnews.com - April 14 at 7:18 PM
	BRIEF-TherapeuticsMD Enters Into Negotiations With US FDA For TX-004HR www.reuters.com - April 13 at 8:20 AM
	TherapeuticsMD (TXMD) Upgraded to "Hold" by Zacks Investment Research www.americanbankingnews.com - April 11 at 1:23 PM
	TherapeuticsMD Enters Into Label Negotiations for TX-004HR finance.yahoo.com - April 11 at 8:32 AM
	TherapeuticsMD (TXMD) PT Set at $10.00 by Deutsche Bank www.americanbankingnews.com - April 9 at 10:52 PM
	TherapeuticsMD (TXMD) PT Set at $10.00 by Oppenheimer www.americanbankingnews.com - April 6 at 10:22 PM
	TherapeuticsMD (TXMD) Stock Rating Upgraded by BidaskClub www.americanbankingnews.com - April 5 at 6:21 PM
	TherapeuticsMD (TXMD) Upgraded at ValuEngine www.americanbankingnews.com - April 2 at 10:52 PM
	TherapeuticsMD Announces Expansion of Board of Directors finance.yahoo.com - April 2 at 8:41 AM
	TherapeuticsMD (TXMD) Upgraded to Sell by BidaskClub www.americanbankingnews.com - March 30 at 10:02 PM
	TherapeuticsMD Inc (TXMD) Expected to Announce Quarterly Sales of $4.21 Million www.americanbankingnews.com - March 30 at 1:52 AM
	TherapeuticsMD (TXMD) Receives Buy Rating from Oppenheimer www.americanbankingnews.com - March 21 at 7:48 PM
	Quotidian Technical Highlights on Selected Drug Makers Stocks -- Sanofi, Shire, TherapeuticsMD, and Zogenix www.bizjournals.com - March 19 at 5:17 PM
	TherapeuticsMD, New PipelineNDA Development, Analysts Target and PDUFA Date finance.yahoo.com - March 19 at 8:24 AM
	TherapeuticsMD Inc (TXMD) Receives Consensus Recommendation of "Buy" from Brokerages www.americanbankingnews.com - March 18 at 3:42 AM
	Brokerages Expect TherapeuticsMD Inc (TXMD) to Post -$0.09 EPS www.americanbankingnews.com - March 11 at 2:12 PM
	TherapeuticsMD Inc (TXMD) Short Interest Update www.americanbankingnews.com - March 11 at 1:58 AM
	The 5 Most Shorted Nasdaq Stocks www.msn.com - March 10 at 6:23 PM
	TherapeuticsMD (TXMD) Given "Buy" Rating at Noble Financial www.americanbankingnews.com - March 10 at 5:09 PM
	Therapeutics Wins FDA Nod, Stocks Don't Budge www.baystreet.ca - March 9 at 6:49 PM

TherapeuticsMD (NASDAQ:TXMD) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

TherapeuticsMD (NASDAQ:TXMD) Income Statement, Balance Sheet and Cash Flow Statement

TherapeuticsMD (NASDAQ TXMD) Stock Chart for Sunday, May, 27, 2018

Loading chart…

This page was last updated on 5/27/2018 by MarketBeat.com Staff